Keywords: astrazeneca, crestor, beneficial, effects, apolipoprotein, lipid, ratios
AstraZeneca's Crestor has beneficial effects on apolipoprotein and lipid ratios
Article | 13 October 2003
AstraZeneca released new data at the 13th International Symposium on Atherosclerosis in Kyoto, Japan, showing that its statin Crestor (rosuvastatin) ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
- Proposal to list Roche's Neulastim and Actemra in New Zealand
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
- Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
